First Principles: What CDD Actually Tests About Pricing

Commercial due diligence in private equity has a process problem. The process is designed to describe the target company. The job of CDD is to test whether the thesis that justified your entry price is actually true.

Those are different tasks. Description produces findings that confirm what you already believed. Testing produces findings that could change whether you do the deal at all, and at what price.

Most CDD processes run description. They confirm market size, competitive position, customer satisfaction, and current pricing against benchmarks. They produce a report that says the company is as described and there is pricing upside. Then the deal closes. Then the pricing upside turns out to be pricing ceiling.

The difference between these outcomes is whether CDD was built from first principles or built from a template.

The Silent Cost

A CDD process that runs on templates rather than first principles has a predictable output: findings that confirm the investment thesis rather than stress-test it. This is not a problem of analyst effort. It is a problem of design.

When CDD is designed to answer "is this company as described?" it will find that yes, broadly, it is as described. When it is designed to answer "will the commercial thesis that justifies our entry price prove correct over a 36 to 48 month hold?" it will find specific points of fragility that the description-based process missed entirely.

The financial cost of template-based CDD compounds. A deal that enters with unvalidated pricing power assumptions will underperform those assumptions. When net revenue retention (NRR) runs 7 points below model for 24 months, the annual recurring revenue (ARR) shortfall is real and the exit valuation takes a double hit: lower ARR base and a compressed multiple because forward projections are discounted.

In dollar terms, on a deal with $40 million ARR at entry and a 36-month hold, a 7-point NRR miss over two years of the hold means roughly $5.6 million of ARR shortfall before exit. At a 7x exit multiple, that is $39 million of enterprise value that did not exist because CDD confirmed the benchmark rather than testing the assumption.

The Operating Model

Step 1: Identify what your thesis actually requires to be true about pricing.

Your entry multiple is an expression of beliefs about future commercial performance. Write down the three commercial beliefs that justify the highest 20 percent of your entry price. Typically: that NRR will sustain or expand, that annual contract value (ACV) will grow through upsell and pricing, and that the ideal customer profile (ICP) will support price increases without meaningful churn.

These are your CDD targets. You are not looking for these to be confirmed. You are looking for the conditions under which they would fail to be true, and testing whether those conditions exist.

Step 2: Rebuild your interview protocol around falsification rather than description.

A standard CDD interview asks customers to describe their experience, rate satisfaction, and comment on alternatives. A first-principles CDD interview starts with the falsification question: "Under what circumstances would you stop using this product or significantly reduce your spend?"

That question is harder to answer and harder to analyze than a satisfaction score. But it directly tests the retention and pricing power assumptions in your thesis.

Follow it with: "If the price increased 20 percent at your next renewal, what would your internal approval process look like?" This tells you whether pricing power is a product property or a budget property. Products with switching costs survive 20 percent price increases because the switching cost is higher than the price increase. Products without switching costs do not, regardless of customer satisfaction.

Step 3: Read the cohort data as a historical experiment, not as a performance summary.

The cohort retention table your target provides is not just a performance report. It is a record of experiments the company has already run, most of them accidentally.

When pricing changed and a cohort's NRR shifted, that is a pricing experiment. When a segment's retention diverged from the rest of the book of business, that is a segmentation experiment. When expansion revenue dried up in a specific tenure band, that is a packaging experiment.

Read the cohort data as an anthropologist reading field notes, not as a finance analyst reading a summary. The patterns you find there are more reliable than any customer interview because they reflect actual behavior rather than stated intent.

When This Fails

A private equity (PE) firm ran CDD on a cybersecurity SaaS company with $28 million ARR and 112 percent NRR. The CDD report confirmed market leadership in a growing segment, strong customer satisfaction scores, and pricing 15 percent below the market rate. The recommendation was "proceed with targeted price increase post-close."

The cohort data in the data room showed something different. NRR in the 24-to-36-month customer cohort was 91 percent, down from 116 percent in the 0-to-12-month cohort and 108 percent in the 12-to-24-month cohort. This pattern means customers were churning or contracting in their third year, which is typically a contract renewal. No one in the CDD process had read the cohort data at this level of resolution.

At 26 months post-close, the cohort that had been 12 to 24 months old at entry hit its renewal cycle. NRR in that cohort was 88 percent. The pattern repeated. Customers were staying through their first and second years, then churn spiked at third-year renewal.

The operating partner eventually diagnosed the issue: the product solved an acute problem in the first 24 months of deployment, but customers were not finding new value to justify renewal pricing in year three. It was not a price problem. It was a product value problem at a specific customer tenure. It was visible in the cohort data that was in the data room at the time of CDD.

The hold was extended by 14 months while a product roadmap was built to address third-year retention. The MOIC was 2.1x on a deal that had underwritten to 3.3x.

Your Next Seven Days

Take your most recent CDD data room request list. Find the request for cohort retention data. If you asked for "NRR for the last four quarters," change it now to: "cohort NRR by acquisition year and plan tier for the last 36 months, with notation of any cohort that experienced a price change."

Then add one new interview question to your protocol: "Under what circumstances would you stop using or significantly reduce your spend on this product?"

Those two changes, one data request and one interview question, represent the difference between template CDD and first-principles CDD. They are free to implement and they will change what you find.

For a framework that applies first-principles analysis to pricing at every stage of diligence and the hold period, use the FintastIQ Pricing Diagnostic.

To see how first-principles CDD connects to post-close value creation, see our post on what CDD must confirm about pricing before any scale investment. To walk through your current CDD process against these questions, Assess Your Pricing Health.